Gairo, 500 mg 10 pcs

Pharmacodynamics

Active against trichomonads, giardia, dysentery amoeba, some anaerobic microorganisms (bacteroides, fusobacteria, some strains of clostridia, anaerobic cocci).

Pharmacokinetics

Gastrointestinal absorption is high. Bioavailability – 90%. Tmax – 1-2 hours. Binding to plasma proteins – at least 15%. It penetrates through the BBB. T1/2 is about 13 hours. It is excreted as metabolites by kidneys (60-70%) and with feces (20-25%), about 5% of dose is excreted unchanged.

Indications

Trichomoniasis, amoebiasis, giardiasis, prevention of infections caused by anaerobic bacteria during operations on the colon and gynecology.

Pharmacological effect

Pharmacodynamics

Active against Trichomonas, Giardia, dysenteric amoeba, some anaerobic microorganisms (bacteroides, fusobacteria, some strains of clostridia, anaerobic cocci).

Pharmacokinetics

Absorption from the gastrointestinal tract is high. Bioavailability – 90%. Tmax – 1-2 hours. Plasma protein binding – at least 15%. Penetrates through the BBB. T1/2 – about 13 hours. Excreted in the form of metabolites by the kidneys (60–70%) and with feces (20–25%), about 5% of the dose is excreted unchanged.

Special instructions

When treating trichomoniasis, both partners should be treated simultaneously.

Active ingredient

Ornidazole

Composition

Film-coated tablets 1 table.

ornidazole500 mg

excipients:

MCC;

lactose;

Aerosil-200;

povidone (K-30);

magnesium stearate;

purified talc;

purified water;

sodium lauryl sulfate;

croscarmellose sodium

shell:

hypromellose (HPMC E-15); polyethylene glycol 400; purified talc; quinoline yellow; brilliant green; titanium dioxide; isopropyl alcohol; dichloromethane; polyethylene glycol 6000; distilled water

Pregnancy

Contraindicated in the first trimester of pregnancy. Breastfeeding should be stopped during treatment.

Contraindications

Hypersensitivity, central nervous system diseases, pregnancy (first trimester), breastfeeding period.

Side Effects

Headache, dizziness, impaired consciousness, tremor, muscle rigidity, incoordination, convulsions, sensory or mixed peripheral neuropathy, nausea, vomiting, diarrhea.

Interaction

Enhances the effect of coumarin anticoagulants and prolongs the muscle relaxant effect of vecuronium bromide. Compatible with alcohol (does not inhibit acetaldehyde dehydrogenase).

Overdose

Symptoms: epileptiform seizures, depression, peripheral neuritis.

Treatment: symptomatic therapy (diazepam for seizures).

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 30 °C

Shelf life

3 years

Manufacturer

Panacea Biotech, India